Abstract 13320: Severe Functional Tricuspid Valve Regurgitation: Predictors of Malignant Disease and Implications on Patient Selection for Trans-Catheter Therapy.

Background: Severe functional tricuspid regurgitation (TR) is associated with poor outcomes. We sought to examine the predictors of early mortality and if severe TR with heart failure (HF) is a stage too late for intervention. Methods: Our study retrospectively identified 635 consecutive patients who had severe functional TR diagnosed on trans-thoracic echocardiography in an academic medical centre from 2000- 2016. We assessed their underlying comorbidities and analyzed their impact on survival. Results: Mean follow-up was 1084 days. There were 371 (58.4%) females, and the mean age at diagnosis was 68.6 years. The mean Body Mass Index, left ventricular ejection fraction (LVEF) and pulmonary artery systolic pressure (PASP) were 23.8 kg/m2, 48.6% and 53.8 mmHg, respectively. Pre-existing or incident atrial fibrillation (AF) and ischemic heart disease were 420 (66.1%) and 312 (49.1%) respectively. A total of 307 (48.4%) patients had HF prior and 123 (19.4%) had incident HF. The mechanisms for severe TR were left heart disease ± pulmonary hypertension (72 %), AF with annular modeling (20.4 %), and isolated right ventricular dilatation (7.6 %). There were 286 (45.0%) deaths during follow up, with 154 (24.3%) dying within a year. The median survival was about 690 days. Multivariate analysis revealed that age at diagnosis (HR 1.03, p: 0.001), prior HF admission (HR: 1.31, p: 0.048), PASP of more than 50 mmHg (HR: 1.48, p: 0.004) and LVEF less than 50% (HR: 1.35, p: 0.041) were significantly associated with time to death. Conclusion: In patients with severe functional TR, advanced age, prior HF admission, LVEF <50%, PASP >50 mm Hg are malignant features, representing an advanced stage of the disease and associated with early mortality. Ability to interpret effectiveness of trans-catheter therapies in this group of patients may be limited, which future clinical intervention trials should take into account. [ABSTRACT FROM AUTHOR]